Inicio・Lista de Acciones・Sana Biotechnology Inc

Sana Biotechnology Inc

Cerrado

SectorSanidad

3.56 -3.26

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.38

Máximo

3.65

Métricas clave
By Trading Economics
Ingresos	-16M -64M
BPA	-0.13
Empleados	142
EBITDA	-21M -65M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+117.98% upside

Dividendos
By Acuity
Próximas Ganancias	4 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	120M 1B
Apertura anterior	6.82
Cierre anterior	3.56

Noticias sobre sentimiento de mercado

By Acuity

25%

75%

87 / 340 Clasificación en Healthcare

Sana Biotechnology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 ago 2026, 20:06 UTC

News

Sana Biotechnology shares declined amid mixed analyst ratings and broader market challenges, with BofA lowering its price target to $6.00 from $7.00.

13 ago 2026, 19:36 UTC

Sana Biotechnology Inc shares are lower today, continuing a decline since Wednesday. The price remains above its 20-day moving average.

12 ago 2026, 23:46 UTC

Sana Biotechnology Inc shares are lower in after-market hours, with no specific news identified to explain the price movement.

11 ago 2026, 19:31 UTC

News

Sana Biotechnology shares are higher following Q2 results showing an adjusted EPS of -$0.13, exceeding estimates, and a $25 million investment from Mayo Clinic.

10 ago 2026, 23:01 UTC

News

Sana Biotechnology Inc shares are lower in after-market hours following a second-quarter loss of $63.6 million, despite an adjusted EPS that exceeded expectations.

7 ago 2026, 19:56 UTC

Sana Biotechnology Inc. shares are higher, supported by broader market dynamics following a disappointing jobs report easing interest rate concerns.

5 ago 2026, 19:56 UTC

Sana Biotechnology Inc. is trading higher during Wednesday's session, having peaked earlier before pulling back slightly while remaining above its 20-day moving average.

4 ago 2026, 20:05 UTC

Sana Biotechnology Inc shares are higher, reflecting strong performance amid a decline in crude oil prices, which may ease inflationary pressures.

3 ago 2026, 19:46 UTC

Sana Biotechnology Inc is higher today, benefiting from a broader market rally, particularly in technology, despite earlier session pullbacks.

31 jul 2026, 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, retracing from earlier gains. Broader market trends show mixed sentiment among major tech firms.

30 jul 2026, 19:29 UTC

Sana Biotechnology Inc shares are higher today, recovering from earlier lows. The stock has shown an upward trend since Wednesday's close.

29 jul 2026, 23:36 UTC

Sana Biotechnology Inc shares are higher in after-market hours, reflecting a slight increase since Wednesday's close amid routine market activity and broader volatility.

28 jul 2026, 18:03 UTC

Sana Biotechnology Inc. shares are higher as biotechnology stocks advance, though they diverge from a recent trend of daily gains since Monday's close.

27 jul 2026, 19:07 UTC

Sana Biotechnology Inc shares are higher today, continuing a rally since Friday. No specific news has been identified to explain the price movement.

24 jul 2026, 18:26 UTC

Sana Biotechnology Inc. shares are trading lower amid broader market volatility, with no specific company news identified to explain the decline.

22 jul 2026, 19:36 UTC

News

Sana Biotechnology has shifted focus to B-cell autoimmune disorders amid competition in oncology. Shares are higher since Tuesday, supported by rising crude oil prices.

20 jul 2026, 17:56 UTC

Social Media

Sana Biotechnology Inc shares are lower, continuing a nine-session decline. Social media discussions raise skepticism about the timeline for its allogeneic cell therapies.

Comparación entre iguales

Cambio de precio

Sana Biotechnology Inc previsión

Precio Objetivo

By TipRanks

117.98% repunte

Estimación a 12 Meses

Media 8 USD 117.98%

Máximo 12 USD

Mínimo 6 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sana Biotechnology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Sana Biotechnology Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

87 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.